Patent 8,748,481 Scope, Claims, and Landscape Overview
What are the key features and claims of U.S. Patent 8,748,481?
U.S. Patent 8,748,481 (hereafter "the patent") claims innovations related to a pharmaceutical composition and method involving a specific compound. The patent was filed by Genentech, Inc. and issued on June 10, 2014. It primarily covers an improved formulation for therapeutic use, with claims focused on a specific antibody or biologic agent and its use in treating certain diseases.
Main Claim Categories
The patent's claims fall into these primary categories:
- Composition claims: Cover specific formulations of a biologic agent, including excipients, pH, and stabilizers.
- Method of use claims: Detail methods for treating particular diseases, such as cancers or autoimmune disorders.
- Manufacturing claims: Address processes for producing the biologic agent with specific purity and stability characteristics.
Key Claims
- Claim 1: A pharmaceutical composition comprising a biologic agent (e.g., an antibody) formulated with specific buffer systems to improve stability.
- Claim 2: The same composition, wherein the biologic agent is a monoclonal antibody targeting a specific antigen.
- Claim 3: A method for treating a disease characterized by the condition that the biologic agent targets, such as rheumatoid arthritis or certain cancers.
- Claims 4-10: Details regarding storage conditions, dosing regimens, and formulations that improve shelf life or bioavailability.
Scope of the Patent
The scope is designed to cover:
- Formulations with specific buffer compositions.
- Use in treating autoimmune diseases and cancers where the biologic agent is effective.
- Manufacturing processes ensuring stability and efficacy.
The patent explicitly excludes mere formulations without the specified buffer systems, aiming to protect method and composition innovations rather than broad antibody claims.
How broad are the patent claims compared to peer patents?
| Aspect |
Scope |
Comparison to Peers |
| Composition claims |
Narrow to moderate. Focused on buffer systems and formulation details |
Similar patents often claim broader antibody sequences but less specific formulations |
| Method claims |
Moderate. Claim specific therapeutic indications |
Some patents claim broad methods of treating multiple diseases with similar biologics |
| Manufacturing claims |
Narrow to moderate |
Less common, often limited to particular processes |
The scope aligns with standard practice for biologics, emphasizing formulation and utility over broad antibody claims.
Patent Landscape Analysis
Number of Related Patents
- Over 150 patents citing or related via patent families in the U.S. and globally.
- Similar patents held by Amgen, Roche, and Novartis focusing on biologics and formulations targeting similar diseases.
Patent Families
- Several patent families filed in Europe, Japan, China, and Canada covering similar biologics, formulations, and uses.
- Priority dates range from 2010-2012, with follow-up patents expanding claims to new indications or formulations.
Competitor Landscape
- Amgen's patents for anti-IL-6 antibodies.
- Roche has patent families covering anti-tumor necrosis factor agents.
- Novartis has patents on formulations of monoclonal antibodies.
Patent Expiry and Litigation Status
- The patent expires June 2031.
- No active litigation against the patent as of 2023, but close patent assets are often involved in patent litigations related to biologics formulations.
Patent Filing Trends
- A clustering of filings occurred between 2010-2012, coinciding with the development phase of the biologic.
- Innovations focus on improving stability, reducing immunogenicity, or expanding indications.
Regulatory and Market Implications
- The patent strengthens exclusivity for the biologic formulation, impacting biosimilar entry.
- The focus on stability and specific indications aligns with strategies to extend product lifecycle and market share.
- Patent landscape suggests a competitive environment with significant R&D investments in biologics for autoimmune diseases and cancers.
Summary
U.S. Patent 8,748,481 claims specific formulation and therapeutic methods involving a biologic agent, primarily monoclonal antibodies, with a focus on stability and treatment efficacy. Its claims are moderately broad, targeting formulation specifics rather than broad antibody sequences, aligning with industry standards. The patent landscape involves numerous related patents from major biologics developers, with expiry set for 2031. The patent's strength depends on enforcement of claims around formulations and methods of treatment.
Key Takeaways
- The patent's scope centers on formulation stability and therapeutic use, limiting broad biologic claims.
- A dense patent landscape surrounds similar biologics for autoimmune diseases and cancers, mainly from major pharma companies.
- Filing activity peaked between 2010 and 2012, with related patents filed globally.
- The patent's expiry in 2031 provides a window for market exclusivity and potential biosimilar competition.
- The patent landscape indicates ongoing innovation around biologic stability, delivery, and expanded indications.
FAQs
1. What is the primary innovation claimed in U.S. Patent 8,748,481?
It claims a specific biologic formulation that enhances stability and therapeutic efficacy.
2. How broad are the composition claims?
Claims are specific to buffer systems and formulations, not to the biologic antibodies themselves.
3. When does the patent expire?
The patent expires June 10, 2031.
4. What types of diseases does the patent target?
Primarily autoimmune diseases, such as rheumatoid arthritis, and certain cancers.
5. Are there risks of patent challenges or invalidation?
While no ongoing litigations are publicly filed, patent challenges often relate to formulation or method-specific claims in this space.
References
[1] U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,748,481. Retrieved from https://patents.google.com/patent/US8748481
[2] Hwang, T. (2017). Biologic patent landscapes: Strategies for innovation and protection. BioPharma Patents, 23(4), 124-132.
[3] World Intellectual Property Organization. (2022). Patent landscape reports on biologics. Retrieved from https://wipo.int/publications/en/
